ClinicalTrials.gg
CompletedNCT05047341Updated Jul 1, 2022

A Study of Human Substance Balance and Biotransformation of [14C]SHR0302

A Phase 1 interventional study of SHR0302、[14C]SHR0302 in Rheumatoid Arthritis (RA), sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
11th of 11
6 · median 30
Started
2021
the only one that year
Phase 1
8 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd., this one is the 11th largest by enrollment, is the only one that started in 2021, is one of 8 in phase 1, and was the 6th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Where they have run

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

The study is being conducted to evaluate the absorption, metabolism and excretion of [14C]SHR0302 in healthy Chinese adult male subjects.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form, communicate well with the investigator and be able to complete the trial in strict compliance with the protocol;
  2. Chinese male subjects judged by the investigator to be healthy;
  3. Adults aged 18 to 45 years (including both ends of the spectrum, as at the time of signing the informed consent form);
  4. Weight ≥ 50 kg and a (BMI) in the range of 19 to 26 kg/m2 (both ends inclusive).

Exclusion criteria

Exclusion Criteria:

Ancillary examinations :

  1. Abnormalities in physical examination, vital signs, routine laboratory tests (complete blood cell analysis, blood biochemistry, coagulation, urine routine, stool routine + occult blood), thyroid function, 12-lead , chest CT, abdominal ultrasound (liver, gallbladder, pancreas, spleen and kidney) and other tests of clinical significance.
  2. Resting interval (QTcF) >450 ms obtained on a 12-lead ECG.
  3. Positive for surface antigen or E antigen, antibody, antibody and syphilis antibody.
  4. Screening for novel coronavirus infection with abnormal C-reactive protein or positive novel coronavirus nucleic acid.

    Medication history:

  5. Systemic use of any drug that inhibits or induces within 30 days prior to the screening period (e.g., inducers - bosentan, paracetamol, efavirenz, etravirine, phenobarbital, rifampin, mitotane, phenytoin sodium, carbamazepine, apatamide, etc.; inhibitors - -erythromycin, clarithromycin, fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole, ciprofloxacin, diltiazem, fluvoxamine, nelfinavir, conivaptan, aripitant, crizotinib, imatinib, dronedarone, cyclosporine).
  6. Have used any prescription drugs, over-the-counter medicines, herbal remedies or dietary supplements such as vitamins, calcium supplements within 14 days prior to the screening period.

    Medical and surgery history:

  7. History of any clinically significant illness or disease or condition that, in the opinion of the investigator, may affect the results of the test, including but not limited to circulatory, respiratory, endocrine, neurological, digestive, urinary or haematological, immunological, psychiatric and metabolic disorders.
  8. History of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmias, torsional ventricular tachycardia, ventricular tachycardia, atrioventricular block, QT prolongation syndrome or symptoms of QT prolongation syndrome and family history (indicated by genetic evidence or sudden death of a close relative at a young age due to cardiac causes).
  9. Have undergone major surgery within the 6 months prior to the screening period or where the surgical incision has not fully healed; major surgery includes, but is not limited to, any surgery with significant risk of bleeding, extended general anaesthesia, or incisional or significant traumatic injury.
  10. Allergies, such as a known history of allergy to two or more substances; or a potential allergy to the test drug or its as judged by the investigator.
  11. Haemorrhoids or perianal disease with regular/ongoing blood in the stool, irritable bowel syndrome, inflammatory bowel disease.

    Living habits:

  12. Habitual constipation or diarrhoea.
  13. Alcohol abuse or regular alcohol consumption within the 6 months prior to the screening period, i.e. more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits at 40% alcohol by volume or 150 mL of wine); or an alcohol breath test result of ≥20 mg/dL at the screening period.
  14. Those who smoked more than 5 cigarettes per day or habitually used nicotine-containing products in the 3 months prior to the screening period and were unable to quit during the trial.
  15. Substance abuse or use of soft drugs (e.g. cannabis) 3 months prior to the screening period or hard drugs (e.g. cocaine, amphetamines, phencyclidine, etc.) 1 year prior to the screening period; or a positive urine drug test during the screening period.
  16. Habitual consumption of grapefruit juice or excessive amounts of tea, coffee and/or caffeinated beverages that cannot be abstained from during the trial.

    Others:

  17. Workers exposed to prolonged radiological conditions; or who have had significant radiological exposure (≥2 chest/abdominal CTs, or ≥3 other types of X-ray examinations) or participated in radiopharmaceutical labelling tests within 1 year prior to the test.
  18. People who have a history of needle sickness or blood sickness, have difficulty collecting blood or cannot tolerate venipuncture blood collection.
  19. Participation in any other clinical trial (including clinical trials such as drugs and devices) within 3 months prior to the screening period.
  20. Those who have been vaccinated within 1 month prior to screening or those who are scheduled to be vaccinated during the trial period.
  21. Those who plan to have children or donate sperm during the trial and within 1 year after completion of the trial, or who do not agree that subjects and their spouses should use strict during the trial and within 1 year after completion of the trial (see Annex 1 for details).
  22. Those who have lost or donated up to 400 mL of blood within 3 months prior to the screening period, or those who have received a blood transfusion within 1 month.
  23. Subjects who, in the opinion of the investigator, have any factors that make them unsuitable for this trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Single arm

    Drug: SHR0302、[14C]SHR0302

Interventions

  • DrugSHR0302、[14C]SHR0302

    8 mg SHR0302/ 80 µCi \[14C\]SHR0302, once, D1

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: day 1 to day 11

  2. AUC0-t

    Time frame: day 1 to day 11

  3. AUC0-∞

    Time frame: day 1 to day 11

  4. Tmax

    Time frame: day 1 to day 11

  5. t1/2

    Time frame: day 1 to day 11

  6. CL/F

    Time frame: day 1 to day 11

  7. Vz/F

    Time frame: day 1 to day 11

Secondary outcomes

  1. The incidence and severity of adverse events/serious adverse events

    Time frame: from ICF signing date to approximate day 11

07

Study locations

1 site
  • the first affiliated hospital of Soochow University
    Suzhou, Jiangsu 215006, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Sep 2021, 0 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 0 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2021
First posted
Sep 17, 2021
StartActual
Sep 7, 2021
Primary completionActual
Sep 19, 2021
CompletionActual
Jun 8, 2022
Last update
Jul 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05047341
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Sep 7, 2021
Primary completion
Sep 19, 2021
Completion
Jun 8, 2022
Last update
Jul 1, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion